martin shkreli

On October 13, 2026, "martin shkreli" appeared on the daily trending feed for the first time in the historical panel's record since 2018, drawing roughly 200 trending visits and a 7-day interest score of 9.9. The trigger was a legal filing: the Federal Trade Commission and seven states asked a federal judge in New York to hold Shkreli in contempt for allegedly violating a lifetime ban from the pharmaceutical industry. Search interest is modest in absolute terms but rising, with a 7-day slope of +5.00, and the queries people are using split between the breaking news and long-running curiosity about his biography and whereabouts.

What's driving interest

The FTC and seven states filed a contempt claim in U.S. District Court in Manhattan on Tuesday, alleging Shkreli "flagrantly and repeatedly violated" a 2022 civil court order that banned him for life from the pharmaceutical industry (Source: CNBC). The filing says that since his release from prison in May 2022, Shkreli publicly traded in at least 60 pharmaceutical industry stocks and broadcast his opinions about drug companies through livestreaming and posts on YouTube, X, and Reddit (Source: CNBC). Bloomberg reports the FTC and seven states started contempt proceedings against Shkreli, who served almost seven years in prison for defrauding investors, and that the FTC said he violated the ban by publicly trading pharmaceutical stocks and broadcasting opinions about the industry (Source: Bloomberg.com).

The underlying order stems from a finding that Shkreli organized an anti-competitive scheme to perpetuate Vyera Pharmaceuticals' monopoly on the anti-parasitic drug Daraprim, after raising its price from $17.50 per tablet to $750 (Source: CNBC). A judge ordered him to disgorge more than $64 million, and the 2nd Circuit U.S. Court of Appeals upheld the permanent injunction in January 2024; the Supreme Court declined to take his appeal in October 2024 (Source: CNBC). The new filing asks a judge to order Shkreli to divest any pharmaceutical company stocks he owns and to pay a fine equal to his profits from pharmaceutical stock trading plus prejudgment interest, without the ability to offset losses (Source: CNBC). It also asks for "clear and escalating consequences" for future violations, including financial penalties and potential incarceration (Source: CNBC). FTC Commissioner Mark Meador said, "A lifetime industry ban is only effective if breaches are met with consequences commensurate with the seriousness of the order" (Source: CNBC). The states joining the FTC are New York, California, Illinois, North Carolina, Ohio, Pennsylvania and Virginia (Source: CNBC). The filing also asks the judge to order Shkreli's sister, Leonora Izerne, and his "significant other, Chelsea Voss," to preserve evidence relating to potential violations (Source: CNBC).

What the data shows

The metrics describe a small but accelerating spike rather than a broad cultural moment. The average 7-day interest score is 9.9 on a 0–100 scale, and the 7-day slope is +5.00, meaning search interest is climbing from a low base. Approximate trending traffic of 200 visits is consistent with a single-day news-driven appearance: the term was first seen in the feed on 2026-10-13 with one sighting. The historical panel, which tracks daily trending lists from 2004 to 2025, shows "martin shkreli" appeared on only 5 distinct days across 3 years — first in 2015, last in 2018 — and peaked most often in February. That pattern indicates the name has no steady baseline of search demand; it surfaces episodically when legal or media developments put him back in the news, then fades.

The query mix reinforces that. Breakout and rising related searches include "martin shkreli pharma industry violation," which maps directly to the contempt filing, alongside evergreen biographical queries: "what is martin shkreli net worth," "martin shkreli wiki," "martin shkreli movie," and "what is martin shkreli doing now." Top related searches are similarly retrospective: "martin shkreli wife," "martin shkreli net worth," "martin shkreli jail," "martin shkreli prison," and "martin shkreli wu tang." The presence of "wu tang" among top related searches indicates a persistent association in user queries, while "jail" and "prison" point to his criminal history. In other words, the news event is pulling in users who are also catching up on who he is and what happened to him — a classic pattern when a figure re-enters the news after years off the trending lists.

What to watch

The surge's duration depends on whether the contempt claim produces further developments. Because the term registered only one sighting and roughly 200 trending visits, it is currently a single-news-cycle event; without a court ruling, a response from Shkreli, or additional coverage, interest is likely to decay quickly, as it did after previous appearances in 2015 and 2018. The next concrete steps would be a judge's decision on the requests to force divestiture, impose a profits-based fine, or set escalating penalties including potential incarceration (Source: CNBC). Any ruling on those requests, or a public response from Shkreli on the platforms named in the filing, would give the story a second act. The historical panel's pattern — brief spikes, no sustained baseline — suggests the term will remain event-driven rather than becoming a durable trend. The breakout query "what is martin shkreli doing now" is the one to watch: if it keeps rising after the initial news, that would indicate lingering curiosity beyond the contempt filing itself.

Sources

• Martin Shkreli violated lifetime pharma industry ban, FTC and states say in contempt claim — CNBC
• Shkreli Faces Contempt for Breaking Pharmaceutical Industry Ban — Bloomberg.com